Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Submits NDA For Ambrisentan For PAH

This article was originally published in The Pink Sheet Daily

Executive Summary

Company has requested a priority review, but anticipates receiving a standard 10-month review, pushing the user fee date to Oct. 18.

You may also be interested in...



FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back

The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.

FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back

The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.

Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps

Company plans to go toe-to-toe with PAH competitors, CEO tells JP Morgan Healthcare Conference.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel